

26 Jun 2019 | Interviews

QUOTED. 26 June 2019. David Brachman.

by

GT Medical Technologies' co-founder and CTO, David Brachman, presented clinical results showing the company's GammaTile device may prevent the return of a brain tumor in patients who underwent resection surgery after recurring brain tumors. See what Brachman said about it here.

“The abstract [won the award] because of the amount of detail we were able to give them on how not just effective the therapy was, but also on the lack of harms. The harms we looked into were a deep dive into the surgical side effects and a deep dive on the radiation side effects, benchmarked against expectations.” – David Brachman, co-founder and chief technology officer, GT Medical Technologies

- Find out more: [New Data Confirm Safety Of GT Medical's GammaTile Therapy For Brain Tumors](#)

[Click here](#) for a free trial of *Medtech Insight*